AxeroVision, Inc. Report issue

For profit Phase 2
Founded: Carlsbad CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03598699
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AxeroVision, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

axr-159 (1 trial)

axr-270 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharitis (Phase 2)

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2